ロード中...
Promoter choice: Who should drive the CAR in T cells?
Chimeric antigen receptor (CAR) T cell therapy is an effective treatment for B cell malignancies, with emerging potential for the treatment of other hematologic cancers and solid tumors. The strength of the promoter within the CAR cassette will alter CAR-polypeptide levels on the cell surface of the...
保存先:
| 出版年: | PLoS One |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7380635/ https://ncbi.nlm.nih.gov/pubmed/32706785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0232915 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|